Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer
The efficacy and safety of combination with Cadonilimab and CapeOX Regimen for neoadjuvant treatment of resectable locally advanced adenocarcinoma of the gastro-esophageal junction.
Locally Advanced Unresectable Gastric Adenocarcinoma
DRUG: Oxaliplatin|DRUG: Capecitabine|DRUG: Cadonilimab
Pathologic complete remission rate (PCR), Pathological complete response (pCR) rate is defined as the proportion of participants whose tumor in the stomach and lymph node completely disappeared, as determined by a pathologist., up to 1 years
3-year disease-free survival rate of 3year (DFS), 3 years disease-free survival (DFS) rate is defined as proportion of participants who have no recurrence or metastasis after 3 years of radical treatment, up to 3 years|Major pathological response rate (MPR), Major pathological response (MPR) rate is defined as the proportion of participants whose percentage of residual tumor in the stomach and lymph node decreased to \< 10%, as determined by a pathologist, up to 1 years|Objective response rate(ORR), Overall response rate ( ORR) is defined as proportion of participants who have a best response of CR or PR, up to 3 years|Disease Control Rate (DCR), Disease Control Rate (DCR) is defined as proportion of participants who have a best response of CR#PR or SD, up to 3 years|Adverse Events（AEs）, Defined as the proportion of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), serious adverse event (SAE), assessed by NCI CTCAE v5.0, up to 3 years
This study was a single arm, open-label, single-center clinical study to evaluate the efficacy and safety of combination with Cadonilimab and CapeOX Regimen for neoadjuvant treatment of resectable locally advanced adenocarcinoma of the gastro-esophageal junction.